Immunization with meningococcal outer-membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitidis infection and septic shock

Journal of Infectious Diseases

Volumn 180, Issue 3, 1999, Pages 747-754

  Quakyi, Emmanuel K ^a   Frasch, Carl E ^a   Buller, Nicole ^a   Tsai, Chao Ming ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; GALACTOSAMINE; HUMORAL ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 6; MENINGOCOCCUS VACCINE; OPSONIN; OUTER MEMBRANE PROTEIN; RECOMBINANT INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG EFFICACY; FEMALE; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INTRAPERITONEAL DRUG ADMINISTRATION; MENINGOCOCCOSIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; SEPTIC SHOCK; STRAIN DIFFERENCE;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CYTOKINES; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; LIPOPOLYSACCHARIDES; MENINGOCOCCAL INFECTIONS; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; NEISSERIA MENINGITIDIS; NEUTROPHILS; PHAGOCYTOSIS; SEROTYPING; SHOCK, SEPTIC; SPECIES SPECIFICITY; SURVIVAL RATE;

EID: 0032827896     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314927     Document Type: Article

References (36)

1. 1. Andersen BM, Solberg O, Bryn K, et al. Endotoxin liberation from Neisseria meningitidis isolated from carriers and clinical cases. Scand J Infect Dis 1987;19:409-19.
2. 2. Andersen BM. Endotoxin release from Neisseria meningitidis: relationship between key bacterial characteristics and meningococcal disease. Scand J Infect Dis Suppl 1989;64:1-43.
3. 3. Waage A, Brandzaeg P, Halstensen A, Kieruf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989;169:333-8.
4. 4. Waage A, Halstensen A, Epsevik T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;1:355-7.
5. 5. Heyderman RS, Klein NJ, Levin M. Pathophysiology and management of meningococcal septicaemia. In: David TJ, ed. Recent advances in paediatrics. vol 11. Edinburgh: Churchill Livingstone, 1993:1-18.
6. 6. Morrison DC, Silverstein R, Bright SW, Chen TY, Flebbe LM, Lei MG. Monoclonal antibody to mouse lipopolysaccharide receptor protects mice against the lethal effects of endotoxin. J Infect Dis 1990;162:1063-8.
7. 7. Quakyi EK, Hochstein HD, Tsai C-M. Modulation of the biological activities of meningococcal endotoxins by association with outer membrane proteins is not inevitably linked to toxicity. Infect Immun 1997;65:1972-9.
8. 8. Tsai C-M, Frasch CE, Rivera E, Hochstein HD. Measurement of lipooligosaccharide (endotoxin) in meningococcal protein and polysaccharide preparation for vaccine usage. J Biol Stand 1989;17:249-58.
9. 9. Leeuwenberg JF, Jeunhomme TMAA, Buurman WA. Slow release of soluble TNF receptors by monocytes in vitro. J Immunol 1994;152:4036-43.
10. 10. Joyce DA, Gibbons DP, Green P, Steer JH, Feldmann M, Brennan FM. Tumor necrosis factor and immune interferon synergistically increase transcription of HLA class I heavy-and light-chain genes in vascular endothelium, Eur J Immunol 1994;24:2699-705.
11. 11. de Waal Malefyl R, Abrams J, Bennett B, Figdor CG, Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes in autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174: 1209-20.
12. 12. Abraham E, Raffin TA. Sepsis therapy trials: continued disappointment or reason for hope? JAMA 1994;271:1876-8.
13. 13. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995;273:934-41.
14. 14. Bagby G, Plessala KJ, Wilson LA, Thompson JJ, Nelson S. Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. J Infect Dis 1991;163:83-8.
15. 15. Eskandari MK, Bologos G, Miller C, Nguyen DT, De Forge LE, Remick DG. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992;148: 2724-30.
16. 16. Hack CE, de Groot ER, Felt-Bersma RJF. Increased plasma levels of interleukin-6 in sepsis. Blood 1989;74:1704-10.
17. 17. Hazelzet JA, van der Voort E, Lindemans J, ter Heerdt PGJ, Neijens HJ. Relation between cytokines and routine laboratory data in children with septic shock and purpura. Intensive Care Med 1994;20:371-4.
18. 18. Quakyi EK, Carter PH, Tsai C-M, Marti GE. Immunization with meningococcal membrane bound lipooligosaccharide accelerates granulocyte recovery and enhances lymphocyte proliferation in myelosuppressed mice. Pathobiology 1997;65:26-38.
19. 19. Osborn MJ, Rosen SM, Rothfeld L, Horecker BL. Studies on the gramnegative cell wall. I: evidence for the role of 2-keto-3-deoxyoctonate in the lipopolysaccharide of Salmonella typhimurium. Proc Natl Acad Sci USA 1963;50:499-506.
20. 20. Gibson BW, Melaugh W, Phlllips NJ, Apicella MA, Campagnari AA, Griffiss JM. Investigation of the structural heterogenicity of lipooligosaccharides from pathogenic Haemophilus and Neisseria species and of R-type lipopolysaccharides from Salmonella typhimurium by electrospray mass spectrometry. J Bacteriol 1993;175:2702-12.
21. 21. Smith PK, Krohn RI, Hermanson CT, Mallia AK, Olson FJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150:76-85.
22. 22. Takayama K, Qureshi N, Hyver K, et al. Characterization of a structural series of lipid A obtained from the lipopolysaccharides of Neisseria gonorrhoeae. J Biol Chem 1986;261:10524-31.
23. 23. Galanos C, Freundenberg MA, Reutter W. Galactosamine-induced sensitization of the lethal effects of endotoxin. Proc Natl Acad Sci USA 1979;76: 5939-43.
24. 24. Anderson EL, Bowers T, Mink CM, et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 1994;62:3391-5.
25. 25. Boyum A. Separation of leukocytes from blood and bone marrow. Scand J Clin Invest 1968;21:Suppl 97.
26. 26. Tennant JR. Evaluation of the trypan blue technique for determination of cell viability. Transplantation 1964;2:685-94.
27. 27. Salit IE, van Melle G, Tomalty L. Experimental meningococcal infection in neonatal animals: models for mucosal invasiveness. Can J Microbiol 1984;30:1022-9.
28. 28. Craven DE, Frasch CE. Protection against group B meningococcal disease: evaluation of serotype 2 protein vaccines in a mouse bacteremia model. Infect Immun 1979;26:110-17.
29. 29. Saukkonen K. Experimental meningococcal meningitis in the infant rat. Microb Pathog 1988;4:203-11.
30. 30. Rosenqvist E, Hartung S, Froholm LO, Hoiby EA, Bovre K, Zollinger WD. Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection. J Clin Microbiol 1988;26:1543-8.
31. 31. Rosenqvist E, Hoiby EA, Bjune G, et al. Antibodies against meningococcal lipooligosaccharides after vaccination and meningococcal disease. Presented at Seventh International Pathogenic Conference, West Berlin, Germany, 1990:105.
32. 32. Ross SC, Rosenthal PJ, Berberich HM, Densen P. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement deficient individuals. J Infect Dis 1987;155:1266-75.
33. 33. Ward KN, Fleer A, Verhoef J, Jones DM. Opsonisation and phagocytosis of group B meningococci by polymorphonuclear leukocytes: comparison of sulphanamide sensitive and resistant strains. J Clin Pathol 1987;40: 361-7.
34. 34. Marchant A, Deviere J, Byl B, De Groote D, Vincent JK, Goldman M. Interleukin-10 production during septicaemia. Lancet 1994;343:707-8.
35. 35. Girardin E, Roux-Lombard P, Grau GE, et al. Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 1995;76:20-3.
36. 36. Wallach D, Engelmann H, Nophar Y, et al. Soluble and cell surface receptors for tumor necrosis factor. Agents Actions Suppl 1991;35:51-7.